ProQR Therapeutics N.V. (PRQR)
| Previous Close | 1.8600 |
| Open | 1.9000 |
| Bid | 1.4600 x 200 |
| Ask | 2.4800 x 200 |
| Day's Range | 1.8650 - 2.0700 |
| 52 Week Range | 1.1100 - 3.2900 |
| Volume | |
| Avg. Volume | 224,687 |
| Market Cap | 168.404M |
| Beta (5Y Monthly) | 0.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer™. The opposition was filed in June 2021 with the European Patent Office (EPO) by a strawman against ProQR’s granted patent EP 3 507 366 B1, which relates
- GlobeNewswire
ProQR Announces Year End 2023 Operating and Financial Results
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinicAccelerated development of Axiomer™ for CNS applications via new research partnership with Rett Syndrome Research TrustCompleted divestment of sepofarsen and ultevursen ophthalmic programs to Laboratoires Théa€118.9 million cash and cash equivalents as of December 31, 2023 p
- GlobeNewswire
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended against an opposition filed in Japan against a patent directed to its ADAR-mediated RNA editing platform Axiomer™. The opposition was filed in September 2023 with the Japanese Patent Office by a strawman against ProQR’s granted patent JP 7244922, which is r
